Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort study.
Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort study.
复制标题
DOI：
10.1186/s13054-021-03547-z
复制
发表时间：
2021-04-19
期刊：
影响因子：
--
通讯作者：
Wurfel MM
中科院分区：
文献类型：
--
作者：
Bhatraju PK;Morrell ED;Zelnick L;Sathe NA;Chai XY;Sakr SS;Sahi SK;Sader A;Lum DM;Liu T;Koetje N;Garay A;Barnes E;Lawson J;Cromer G;Bray MK;Pipavath S;Kestenbaum BR;Liles WC;Fink SL;West TE;Evans L;Mikacenic C;Wurfel MM
对参与宿主对严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）病毒感染反应的血液生物标志物进行分析，可以揭示不同的生物学途径，并为COVID-19治疗方法的开发和测试提供信息。我们的目的是评估COVID-19中宿主内皮、上皮和炎症生物标志物。我们前瞻性纳入了2020年4月至9月的171例ICU患者，其中78例（46%）为SARS-CoV-2感染阳性，93例（54%）为阴性。我们比较了22种血浆生物标志物在ICU入院后24小时和3天内采集的血液。在COVID-19危重症和非COVID-19患者中，最常见的ICU入院诊断是呼吸衰竭或肺炎，其次是败血症和其他诊断。在研究入组时，两组患者接受有创机械通气的比例相似。COVID-19和非COVID-19患者的急性呼吸窘迫综合征、严重急性肾损伤和住院死亡率相似。虽然白细胞介素6和8的浓度在两组之间没有差异，但与非COVID-19相比，COVID-19患者的上皮细胞损伤标志物（晚期糖基化终产物可溶性受体，sRAGE）和急性期蛋白（血清淀粉样蛋白A， SAA）明显更高，调整了人口统计学和APACHE III评分。相比之下，血管生成素2:1 （Ang-2:1）和可溶性肿瘤坏死因子受体1 (sTNFR-1)（内皮功能障碍和炎症标志物）在COVID-19中显著降低（p < 0.002）。Ang-2:1比和SAA仅与非covid -19患者的死亡率相关。这些研究表明，与其他研究充分的危重疾病原因不同，内皮功能障碍可能不是重症COVID-19入院后早期的特征。导致急性期蛋白精化和诱导上皮细胞损伤的途径可能是治疗COVID-19的有希望的靶点。在线版本包含补充材料，可在10.1186/s13054-021-03547-z获得。
Analyses of blood biomarkers involved in the host response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection can reveal distinct biological pathways and inform development and testing of therapeutics for COVID-19. Our objective was to evaluate host endothelial, epithelial and inflammatory biomarkers in COVID-19. We prospectively enrolled 171 ICU patients, including 78 (46%) patients positive and 93 (54%) negative for SARS-CoV-2 infection from April to September, 2020. We compared 22 plasma biomarkers in blood collected within 24 h and 3 days after ICU admission. In critically ill COVID-19 and non-COVID-19 patients, the most common ICU admission diagnoses were respiratory failure or pneumonia, followed by sepsis and other diagnoses. Similar proportions of patients in both groups received invasive mechanical ventilation at the time of study enrollment. COVID-19 and non-COVID-19 patients had similar rates of acute respiratory distress syndrome, severe acute kidney injury, and in-hospital mortality. While concentrations of interleukin 6 and 8 were not different between groups, markers of epithelial cell injury (soluble receptor for advanced glycation end products, sRAGE) and acute phase proteins (serum amyloid A, SAA) were significantly higher in COVID-19 compared to non-COVID-19, adjusting for demographics and APACHE III scores. In contrast, angiopoietin 2:1 (Ang-2:1 ratio) and soluble tumor necrosis factor receptor 1 (sTNFR-1), markers of endothelial dysfunction and inflammation, were significantly lower in COVID-19 (p < 0.002). Ang-2:1 ratio and SAA were associated with mortality only in non-COVID-19 patients. These studies demonstrate that, unlike other well-studied causes of critical illness, endothelial dysfunction may not be characteristic of severe COVID-19 early after ICU admission. Pathways resulting in elaboration of acute phase proteins and inducing epithelial cell injury may be promising targets for therapeutics in COVID-19. The online version contains supplementary material available at 10.1186/s13054-021-03547-z.
登录
查看更多内容
影响因子：
8.3
作者：
Cobb NL;Sathe NA;Duan KI;Seitz KP;Thau MR;Sung CC;Morrell ED;Mikacenic C;Kim HN;Liles WC;Luks AM;Town J;Pipavath S;Wurfel MM;Hough CL;West TE;Bhatraju PK
通讯作者：
Bhatraju PK
DOI：
10.1056/nejmoa2028836
发表时间：
2020-12-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
Stone JH;Frigault MJ;Serling-Boyd NJ;Fernandes AD;Harvey L;Foulkes AS;Horick NK;Healy BC;Shah R;Bensaci AM;Woolley AE;Nikiforow S;Lin N;Sagar M;Schrager H;Huckins DS;Axelrod M;Pincus MD;Fleisher J;Sacks CA;Dougan M;North CM;Halvorsen YD;Thurber TK;Dagher Z;Scherer A;Wallwork RS;Kim AY;Schoenfeld S;Sen P;Neilan TG;Perugino CA;Unizony SH;Collier DS;Matza MA;Yinh JM;Bowman KA;Meyerowitz E;Zafar A;Drobni ZD;Bolster MB;Kohler M;D'Silva KM;Dau J;Lockwood MM;Cubbison C;Weber BN;Mansour MK;BACC Bay Tocilizumab Trial Investigators
通讯作者：
BACC Bay Tocilizumab Trial Investigators
影响因子：
39
作者：
Gupta, Shruti;Hayek, Salim S.;Leaf, David E.
通讯作者：
Leaf, David E.
DOI：
10.1001/jama.2020.6775
发表时间：
2020-01-01
期刊：
JAMA, Journal of the American Medical Association
影响因子：
--
作者：
Richardson, Safiya;Hirsch, Jamie S.;,
通讯作者：
,
影响因子：
9.8
作者：
Smadja, David M.;Guerin, Coralie L.;Diehl, Jean-Luc
通讯作者：
Diehl, Jean-Luc